Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Hematologic Cancers
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Pegylated Interferon Controlled Extreme Thrombocytosis, Well-Tolerated in Younger Patients With MPN
A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.
Effects of Daratumumab on Patient-Reported Outcomes, HRQOL in Newly Diagnosed Multiple Myeloma
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Integrated Palliative, Oncology Care Improves Quality of Life in Acute Myeloid Leukemia
Investigators assessed the effectiveness of integrated palliative and oncology care on end-of-life outcomes in patients with acute myeloid leukemia.
Comparing Adolescents’ Understanding of Cancer Prognosis With Health Care Providers, Caregivers
Investigators aimed to understand how well adolescents with cancer understand their prognosis compared with their health care providers and caregivers.
Beta Blocker Usage Associated With Prolonged PFS in R/R Multiple Myeloma
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Subcutaneous Bortezomib Plus Panobinostat May Reduce Toxicity in Relapsed, Refractory Multiple Myeloma
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
Xpovio Multiple Myeloma Indication Expanded
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
-
Loading...
-
Loading...
Next post in Multiple Myeloma
